- Home
- ABTS vs LYRA Comparison
ABTS vs LYRA Comparison
Compare ABTS & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- LYRA
- Stock Information
- Founded
- ABTS 2010
- LYRA 2005
- Country
- ABTS Hong Kong
- LYRA United States
- Employees
- ABTS N/A
- LYRA 30
- Industry
- ABTS Computer Software: Programming Data Processing
- LYRA Medical/Dental Instruments
- Sector
- ABTS Technology
- LYRA Health Care
- Exchange
- ABTS Nasdaq
- LYRA Nasdaq
- Market Cap
- ABTS 9.8M
- LYRA 11.6M
- IPO Year
- ABTS N/A
- LYRA 2020
- Fundamental
- Price
- ABTS $4.21
- LYRA $7.05
- Analyst Decision
- ABTS
- LYRA Buy
- Analyst Count
- ABTS 0
- LYRA 2
- Target Price
- ABTS N/A
- LYRA $16.00
- AVG Volume (30 Days)
- ABTS 16.7K
- LYRA 28.3K
- Earning Date
- ABTS 08-13-2025
- LYRA 08-12-2025
- Dividend Yield
- ABTS N/A
- LYRA N/A
- EPS Growth
- ABTS N/A
- LYRA N/A
- EPS
- ABTS N/A
- LYRA N/A
- Revenue
- ABTS $7,037,156.00
- LYRA $770,000.00
- Revenue This Year
- ABTS N/A
- LYRA N/A
- Revenue Next Year
- ABTS N/A
- LYRA $139.18
- P/E Ratio
- ABTS N/A
- LYRA N/A
- Revenue Growth
- ABTS 31.69
- LYRA N/A
- 52 Week Low
- ABTS $1.35
- LYRA $3.81
- 52 Week High
- ABTS $14.10
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- ABTS 49.33
- LYRA 41.94
- Support Level
- ABTS $3.87
- LYRA $6.51
- Resistance Level
- ABTS $4.44
- LYRA $7.57
- Average True Range (ATR)
- ABTS 0.33
- LYRA 0.55
- MACD
- ABTS 0.00
- LYRA 0.14
- Stochastic Oscillator
- ABTS 65.74
- LYRA 47.71
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.